PURPOSE:
The technology is intended for early laboratory diagnosis of oncohematological diseases.
DESCRIPTION:
Leukemic stem cells (LSC) initiate the onset of hemoblastoses and should be targeted by new therapies. Of the 400 leukocyte antigens, markers characteristic of LSC were selected and technology for their identification was developed during early diagnosis of leukemia in about 4000 patients in Ukraine in accordance with the WHO classification. This is of fundamental importance for prescribing targeted therapy, predicting the risk of relapse and identifying minimal residual disease. Precision diagnostic studies of blood cells and bone marrow will be carried out in 1750-2000 patients annually using the developed immunocytochemical methods and a wide panel of monoclonal antibodies to linearly specific and differentiating surface membrane antigens. To analyze the phenotype of leukemic cells, the use of flow cytometry is also provided. This will increase the effectiveness of individualized therapy of patients with the use of modern drugs aimed exclusively at LSC.
ADVANTAGES:
Due to the use of the proposed innovative technology, which has no analogues in the world, and the project will be fully implemented, up to 10 thousand diagnostic tests will be carried out annually with the simultaneous identification of LSC in patients with oncohematological pathology in Ukraine.
RECOMMENDED FIELD OF APPLICATION:
Creation of the first in our country State Specialized Consultative and Diagnostic Center for Oncohematological Diseases, which will serve patients from all regions of Ukraine.
RESULTS OF THE RESEARCH:
Put into production.
STAGE OF THE DEVELOPMENT READINESS:
Put into production.
TRANSFER OPPORTUNITY:
Sales of finished products.
NOVELTY:
5 patents of Ukraine.
IF YOU ARE INTERESTED IN THIS DEVELOPMENT, PLEASE,
WRITE TO US